Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
New report highlights cancer’s toll on racial and ethnic minorities and other underserved populations.
Study suggests immune-based cancer therapies might be particularly beneficial for HIV-positive people.
This held particularly true for prostate and breast cancers in a recent analysis.
September is Prostate Cancer Awareness Month and the perfect time to learn more about this common cancer.
The cancer rate of those living with HIV in the U.S. is expected to decline in the next decade.
Declining rates are expected for Kaposi sarcoma, non–Hodgkin lymphoma, cervical and lung cancer and Hodgkin lymphoma, among others.
However, older people with HIV have a lower rate of a few other cancers compared with the general population.
As AIDS-related cancers decline and the HIV population ages, the most common malignancies by 2030 will likely be those related to aging.
HIV-positive people are apparently less likely to receive treatment for cancer when compared with those who do not have the virus.
Men living with HIV enjoy a diminished risk of prostate cancer that is not an apparent result of differences in screening or other various ris...
The first POZ cover guy reflects on the aftermath of his revealing 1994 interview and his life today.
High-dose supplementation with selenium and vitamin E can raise the risk of high-grade prostate cancer among certain men.
People who start antiretroviral (ARV) treatments at higher CD4 cell counts are less likely to develop non-AIDS-related cancers
Promoting testosterone replacement therapy
As people with HIV survive longer, diseases with long latency periods notably non-AIDS cancers and cardiovascular disease are emerging.
Four antiretrovirals (ARVs), notably Merck’s integrase inhibitor Isentress (raltegravir), can inhibit a virus linked to prostate cancer and ch...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.